Chart: Inside JUPITER's Realm: A Closer Look At The Trial Results
Executive Summary
AstraZenenca's JUPITER study pushes the boundaries of the statin class to a new level. The latest large-scale outcomes trial for the statin class, using AstraZenenca's Crestor (rosuvastatin), explores use in a population that has healthy LDL cholesterol levels but with high levels of an inflammation biomarker that predicts future cardiovascular events: high-sensitivity C-reactive protein.
You may also be interested in...
Analysts Bullish On Crestor After Strong JUPITER Data
JPMorgan raises global sales estimate but cautions that AstraZeneca has under-invested in the statin.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials